Log in

NASDAQ:BMRNBioMarin Pharmaceutical Stock Price, Forecast & News

$119.65
-0.18 (-0.15 %)
(As of 08/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$118.36
Now: $119.65
$120.66
50-Day Range
$111.32
MA: $124.14
$131.03
52-Week Range
$62.88
Now: $119.65
$131.95
Volume642,581 shs
Average Volume1.06 million shs
Market Capitalization$21.64 billion
P/E Ratio181.29
Dividend YieldN/A
Beta1.05
BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder; and Firdapse for lambert eaton myasthenic syndrome. Its clinical and pre-clinical product pipeline includes valoctocogene roxaparvovec, an adeno associated virus vector drug development candidate in patients with severe hemophilia A; and vosoritide, a peptide therapeutic for the treatment of achondroplasia, a form of disproportionate short stature in humans. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has collaboration and license agreements with Sarepta Therapeutics and Asubio Pharma Co., Ltd. The company was founded in 1996 and is headquartered in San Rafael, California.
Read More
BioMarin Pharmaceutical logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.67 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:BMRN
CUSIP09061G10
Phone415-506-6700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.70 billion
Cash Flow$0.64 per share
Book Value$17.38 per share

Profitability

Net Income$-23,850,000.00

Miscellaneous

Employees3,001
Market Cap$21.64 billion
Next Earnings Date10/28/2020 (Estimated)
OptionableOptionable
$119.65
-0.18 (-0.15 %)
(As of 08/6/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











BioMarin Pharmaceutical (NASDAQ:BMRN) Frequently Asked Questions

How has BioMarin Pharmaceutical's stock been impacted by COVID-19 (Coronavirus)?

BioMarin Pharmaceutical's stock was trading at $86.90 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BMRN shares have increased by 37.7% and is now trading at $119.65.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of BioMarin Pharmaceutical?

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last year. There are currently 6 hold ratings and 17 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for BioMarin Pharmaceutical
.

When is BioMarin Pharmaceutical's next earnings date?

BioMarin Pharmaceutical is scheduled to release its next quarterly earnings announcement on Wednesday, October 28th 2020.
View our earnings forecast for BioMarin Pharmaceutical
.

How were BioMarin Pharmaceutical's earnings last quarter?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced its quarterly earnings results on Tuesday, August, 4th. The biotechnology company reported $0.07 earnings per share for the quarter, beating analysts' consensus estimates of ($0.10) by $0.17. The biotechnology company earned $429.49 million during the quarter, compared to analysts' expectations of $418.02 million. BioMarin Pharmaceutical had a net margin of 6.62% and a return on equity of 4.40%.
View BioMarin Pharmaceutical's earnings history
.

What guidance has BioMarin Pharmaceutical issued on next quarter's earnings?

BioMarin Pharmaceutical updated its FY 2020 After-Hours earnings guidance on Tuesday, August, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.85-1.95 billion, compared to the consensus revenue estimate of $1.9 billion.

What price target have analysts set for BMRN?

23 Wall Street analysts have issued 1 year price objectives for BioMarin Pharmaceutical's shares. Their forecasts range from $77.00 to $156.00. On average, they anticipate BioMarin Pharmaceutical's share price to reach $125.27 in the next year. This suggests a possible upside of 4.7% from the stock's current price.
View analysts' price targets for BioMarin Pharmaceutical
.

Has BioMarin Pharmaceutical been receiving favorable news coverage?

News coverage about BMRN stock has been trending positive recently, according to InfoTrie. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. BioMarin Pharmaceutical earned a media sentiment score of 2.1 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future.
View the latest news about BioMarin Pharmaceutical
.

Who are some of BioMarin Pharmaceutical's key competitors?

What other stocks do shareholders of BioMarin Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), Medivation (MDVN), Incyte (INCY), First Solar (FSLR), United Continental (UAL), Dynavax Technologies (DVAX), Kite Pharma (KITE), Celgene (CELG), Array Biopharma (ARRY) and Freeport-McMoRan (FCX).

Who are BioMarin Pharmaceutical's key executives?

BioMarin Pharmaceutical's management team includes the following people:
  • Mr. Jean-Jacques Bienaimé M.B.A., MBA, Chairman & CEO (Age 66)
  • Mr. Daniel K. Spiegelman, Exec. VP & CFO (Age 60)
  • Dr. Robert A. Baffi, Exec. VP of Technical Operations (Age 64)
  • Mr. Jeffrey Robert Ajer, Exec. VP & Chief Commercial Officer (Age 57)
  • Dr. Henry J. Fuchs, Pres of Worldwide R&D (Age 61)

What is BioMarin Pharmaceutical's stock symbol?

BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."

Who are BioMarin Pharmaceutical's major shareholders?

BioMarin Pharmaceutical's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Jennison Associates LLC (4.20%), First Trust Advisors LP (0.63%), Manning & Napier Group LLC (0.54%), Frontier Capital Management Co. LLC (0.42%), Sumitomo Mitsui Trust Holdings Inc. (0.40%) and Swiss National Bank (0.39%). Company insiders that own BioMarin Pharmaceutical stock include Alan Lewis, Brian Mueller, Daniel K Spiegelman, Elaine J Heron, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Michael G Grey, Richard A Meier, Robert Baffi, V Bryan Lawlis and Willard H Dere.
View institutional ownership trends for BioMarin Pharmaceutical
.

Which major investors are selling BioMarin Pharmaceutical stock?

BMRN stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Jennison Associates LLC, Frontier Capital Management Co. LLC, Manning & Napier Group LLC, TCW Group Inc., Scout Investments Inc., Oregon Public Employees Retirement Fund, and EFG Asset Management Americas Corp.. Company insiders that have sold BioMarin Pharmaceutical company stock in the last year include George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Michael G Grey, V Bryan Lawlis, and Willard H Dere.
View insider buying and selling activity for BioMarin Pharmaceutical
.

Which major investors are buying BioMarin Pharmaceutical stock?

BMRN stock was bought by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Strs Ohio, Mckinley Capital Management LLC Delaware, State of Alaska Department of Revenue, Robeco Institutional Asset Management B.V., Janney Montgomery Scott LLC, WINTON GROUP Ltd, and Taylor Wealth Management Partners.
View insider buying and selling activity for BioMarin Pharmaceutical
.

How do I buy shares of BioMarin Pharmaceutical?

Shares of BMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BioMarin Pharmaceutical's stock price today?

One share of BMRN stock can currently be purchased for approximately $119.65.

How big of a company is BioMarin Pharmaceutical?

BioMarin Pharmaceutical has a market capitalization of $21.64 billion and generates $1.70 billion in revenue each year. The biotechnology company earns $-23,850,000.00 in net income (profit) each year or $0.07 on an earnings per share basis. BioMarin Pharmaceutical employs 3,001 workers across the globe.

What is BioMarin Pharmaceutical's official website?

The official website for BioMarin Pharmaceutical is www.bmrn.com.

How can I contact BioMarin Pharmaceutical?

BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The biotechnology company can be reached via phone at 415-506-6700 or via email at [email protected]

This page was last updated on 8/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.